Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy
Brief Summary: This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.


Options:
A: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
B: Arm Label: TAS-102+BSC; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo+BSC; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC
C: Arm Label: Arm N - Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm N-I, Level 1: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2b: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2c: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cobimetinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm N - Nivolumab, Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm N-I, Level 1: Nivolumab+Ipilimumab, Arm N-I, Level 2: Nivolumab+Ipilimumab, Arm N-I, Level 2b: Nivolumab+Ipilimumab, Arm N-I, Level 2c: Nivolumab+Ipilimumab, Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib
D: Arm Label: ONO-4538 Arm; Type: EXPERIMENTAL; Interventions: Drug: ONO-4538 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ONO-4538; Assigned to Arm(s): ONO-4538 Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: A